PromarkerD enables a more comprehensive assessment and informed approach to help:
- Identify patients at risk of developing DKD within the next four years
- Implement preventative measures before kidney damage occurs
- Personalise patient treatment plans
- Improve patient monitoring and management
- Results published in the peer-reviewed journal PLOS ONE show the PromarkerD test ranked as more important to physicians than current standard-of-care tests
What can be done?
Early stage chronic kidney disease can be treated through dietary changes, lifestyle modifications and blood pressure controlling drugs, all of which ensure a relatively better quality of life.
- Janssen’s Invokana® (canagliflozin) – the first FDA approved drug for treating DKD
- Currently ~20 DKD drugs are at different stages of clinical trials
- American Diabetes Association (ADA) & the European Association for the Study of Diabetes (EASD) latest guidelines¹ on managing Type 2 Diabetes recommend that patients with cardiovascular disease take a GLP-1 receptor agonist or SGLT2 inhibitor.
Early detection can significantly help prevent serious kidney damage
1. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia; Diabetes Care https://link.springer.com/article/10.1007/s00125-018-4729-5